PT  - JOURNAL ARTICLE
AU  - Greenland-Bews, Caitlin
AU  - Byrne, Rachel. L.
AU  - Owen, Sophie. I.
AU  - Watkins, Rachel. L.
AU  - Bengey, Daisy
AU  - Buist, Kate
AU  - Clerkin, Karina
AU  - Escadafal, Camille
AU  - Finch, Lorna. S.
AU  - Gould, Susan
AU  - Giorgi, Emanuele
AU  - Hodgkinson, Andy
AU  - Mashenko, Larysa
AU  - Powell, Darren
AU  - Savage, Helen. R.
AU  - Thompson, Caitlin. R.
AU  - Turtle, Lance
AU  - Wardale, Jahanara
AU  - Wooding, Dominic
AU  - Edwards, Thomas
AU  - Atienzar, Ana Cubas
AU  - Adams, Emily. R.
TI  - Evaluation of Eight Lateral Flow Tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population
AID  - 10.1101/2022.04.04.22273232
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.04.22273232
4099  - http://medrxiv.org/content/early/2022/04/07/2022.04.04.22273232.short
4100  - http://medrxiv.org/content/early/2022/04/07/2022.04.04.22273232.full
AB  - With the distribution of COVID-19 vaccinations across the globe and the limited access in many countries, quick determination of an individual’s antibody status could be beneficial in allocating limited vaccine doses in low- and middle-income countries (LMIC). Antibody lateral flow tests (LFTs) have potential to address this need as a quick, point of care test, they also have a use case for identifying sero-negative individuals for novel therapeutics, and for epidemiology. Here we present a proof-of-concept evaluation of eight LFT brands using sera from 95 vaccinated individuals to determine sensitivity for detecting vaccination generated antibodies. All 95 (100%) participants tested positive for anti-spike antibodies by the chemiluminescent microparticle immunoassay (CMIA) reference standard post-dose two of their SARS-CoV-2 vaccine: BNT162b2 (Pfizer/BioNTech, n=60), AZD1222 (AstraZeneca, n=31), mRNA-1273 (Moderna, n=2) and Undeclared Vaccine Brand (n=2). Sensitivity increased from dose one to dose two in six out of eight LFTs with three tests achieving 100% sensitivity at dose two in detecting anti-spike antibodies. These tests are quick, low-cost point-of-care tools that can be used without prior training to establish antibody status and may prove valuable for allocating limited vaccine doses in LMICs to ensure those in at risk groups access the protection they need. Further investigation into their performance in vaccinated peoples is required before more widespread utilisation is considered.Competing Interest StatementEmily Adams is Director of Epidemics and NTDs at Mologic, UK, Sophie Owen is Clinical Affairs Officer at Mologic, UK. Mologic tests were not evaluated in this publication.Funding StatementThis study received funding from the UK Research Council through a PhD scholarship from the MRC Doctoral Training Partnership to CGB. LT is supported by a Wellcome Trust fellowship [205228/Z/16/Z]. For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. LT, TF and EA are supported by the U.S. Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085 and by the National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The NHS Research Ethics Committee (REC, UK) [REC reference:16/NW/0170] and the central Liverpool research ethics committee [Protocol Number: UoL001207] granted ethical approval for this work. The Integrated Research Application System (IRAS) Project ID is: 202413I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authors